Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions,...
Covered in this story
What has happened since
- Lilly (Eli) is up 15.1% since this was published, 39 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Lilly (Eli)
- Cantor Fitzgerald: $1.19k → $1.44k by Oct 2027 · Overweight via Stocktwits
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $LLY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Lilly (Eli) →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.